디에이치엑스컴퍼니

031860KOSDAQ

49.5 / 100

Reference Date: 2026-10-23

Financial Score21.0 / 40

News Sentiment12.5 / 25

Momentum12.0 / 20

Disclosure4.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

DHX Company operates diverse businesses including bicycle manufacturing, ICT distribution, biomedicine development, and regional specialty product exports, with the ICT division contributing over 90% of sales. Key products include the blood purification device 'Hemapure', AI-based brain diagnostic tool 'Neuroharmony', and immunopain treatment drug 'Afitoxin', while also conducting R&D in biocosmetics based on skin microbiome technology.

Number of Employees

27people

Average Salary

5.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.92Industry Average 1.204.0Point

In line with industry avg

ROE

-101.78Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

5.79Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲18.2% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲12.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -63.4% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position8.0Point

Near 52w high (100%, uptrend)

Current 6,930Won52-week high 6,93052-week low 265

1-month return3.0Point

1m 0% (flat)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

10 totalPositive 0Neutral 8Negative 2

Neutral주주총회소집공고2026-10-20
Neutral의결권대리행사권유참고서류2026-10-20
Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-10-16
Negative[기재정정]소송등의제기ㆍ신청(경영권분쟁소송) (이사회결의 효력정지 및 직무집행정지등 가처분)2026-10-15
Neutral기타시장안내 (상장적격성 실질심사 대상결정 기한 안내)2026-10-14